Method for treating cancer
The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
1. A method for treating an INI1-negative tumor comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the INI1-negative tumor is selected from epithelioid malignant peripheral nerve sheath tumor and myoepithelial carcinoma, wherein the subject is younger than 18 years old and wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
2. The method of claim 1 , wherein the INI1-negative tumor is epithelioid malignant peripheral nerve sheath tumor.
3. The method of claim 1 , wherein the INI1-negative tumor is myoepithelial carcinoma.
4. The method of claim 1 , wherein the EZH2 inhibitor is administered orally.
5. The method of claim 1 , wherein the subject is a human being.
6. The method of claim 1 , wherein the EZH2 inhibitor is Compound (A), having the following formula:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID to about 1600 mg BID.
8. The method of claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID, 200 mg BID, 400 mg BID, 800 mg BID, or about 1600 mg BID.
9. The method of claim 8 , wherein the EZH2 inhibitor is administered to the subject at a dose of 800 mg BID.
10. The method of claim 1 , wherein the EZH2 inhibitor is selected from the group consisting of
and pharmaceutically acceptable salts thereof.
11. The method of claim 10 , wherein the EZH2 inhibitor is:
or a pharmaceutically acceptable salt thereof.